SAB Biotherapeutics Inc Total Liabilities
SAB Biotherapeutics Inc total liabilities. Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has total liabilities worth $23.43 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SABS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SAB Biotherapeutics Inc (2019–2025)
Total liabilities of SAB Biotherapeutics Inc from 2019 to 2025. This chart illustrates how SAB Biotherapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore SAB Biotherapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
SAB Biotherapeutics Inc Competitors by Total Liabilities
The table below lists competitors of SAB Biotherapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alico Inc
NASDAQ:ALCO
|
USA | $90.50 Million |
|
Armada Acquisition Corp. II
NASDAQ:XRPN
|
USA | $255.87 Million |
|
i3system Inc
KQ:214430
|
Korea | ₩52.25 Billion |
|
Great Tree Pharmacy Co Ltd
TWO:6469
|
Taiwan | NT$9.76 Billion |
|
Médica Sur S.A.B. de C.V
MX:MEDICAB
|
Mexico | MX$2.19 Billion |
|
Hospital Mater Dei S.A
SA:MATD3
|
Brazil | R$2.87 Billion |
|
First Northern Community Bancorp Common stock
NASDAQ:FNRN
|
USA | $1.71 Billion |
|
Braskem S.A.
SA:BRKM3
|
Brazil | R$90.56 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down SAB Biotherapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of SAB Biotherapeutics Inc.
Liquidity & Leverage Metrics
SAB Biotherapeutics Inc Total Liabilities Ratios Explained
SAB Biotherapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SAB Biotherapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SAB Biotherapeutics Inc (2019–2025)
The table below shows the annual total liabilities of SAB Biotherapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.32 Million | +16.95% |
| 2024-12-31 | $18.23 Million | -31.59% |
| 2023-12-31 | $26.64 Million | +34.24% |
| 2022-12-31 | $19.85 Million | -53.40% |
| 2021-12-31 | $42.59 Million | +142.96% |
| 2020-12-31 | $17.53 Million | -13.68% |
| 2019-12-31 | $20.31 Million | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes … Read more